Ceftaroline Fosamil: Drug Profile And Clinical Data

Bibliography

• Kanafani ZA , FowlerVGJr : [Staphylococcus aureus infections: new challenges from an old pathogen]. Enferm. Infecc. Microbiol. Clin.24(3) , 182–193 (2006).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME , CoreyGR: New treatments for methicillin-resistant Staphylococcus aureus.Curr. Opin. Crit. Care15(5) , 403–412 (2009).
   PubMed Web of Science ®Google Scholar
• Corey GR , WilcoxM, TalbotGHet al. .: Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.Clin. Infect. Dis.51(6) , 641–650 (2010).
   PubMed Web of Science ®Google Scholar
• Talbot GH , ThyeD, DasA, GeY: Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.Antimicrob. Agents Chemother.51(10) , 3612–3616 (2007).
   PubMed Web of Science ®Google Scholar
• Eckburg P , FriedlandHD, LeeJ, LlorensL, CritchleyIA, ThyeD: FOCUS 1 and 2: randomized, double-blinded, multicenter Phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP).49th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA, 12–15 September 2009 (Abstract L1-345a).
   Google Scholar
• Ishikawa T , MatsunagaN, TawadaHet al. : TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.Bioorg. Med. Chem.11(11) , 2427–2437 (2003).
   PubMed Web of Science ®Google Scholar
• Villegas-Estrada A , LeeM, HesekD, VakulenkoSB, MobasheryS: Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA β-lactam antibiotics.J. Am. Chem. Soc.130(29) , 9212–9213 (2008).
   PubMed Web of Science ®Google Scholar
• Moisan H , PruneauM, MalouinF: Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.J. Antimicrob. Chemother.65(4) , 713–716 (2010).
   PubMed Web of Science ®Google Scholar
• Brown SD , TraczewskiMM: In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.Antimicrob. Agents Chemother.53(3) , 1271–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Fenoll A , AguilarL, RobledoOet al. : In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.Antimicrob. Agents Chemother.52(11) , 4209–4210 (2008).
   PubMed Web of Science ®Google Scholar
• Ge Y , BiekD, TalbotGH, SahmDF: In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.Antimicrob. Agents Chemother.52(9) , 3398–3407 (2008).
   PubMed Web of Science ®Google Scholar
• Sader HS , FritscheTR, JonesRN: Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.Antimicrob. Agents Chemother.52(3) , 1153–1155 (2008).
   PubMed Web of Science ®Google Scholar
• Sader HS , FritscheTR, KanigaK, GeY, JonesRN: Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.Antimicrob. Agents Chemother.49(8) , 3501–3512 (2005).
   PubMed Web of Science ®Google Scholar
• Saravolatz L , PawlakJ, JohnsonL: In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.Antimicrob. Agents Chemother.54(7) , 3027–3030 (2010).
   PubMed Web of Science ®Google Scholar
• Vidaillac C , LeonardSN, RybakMJ: In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.Antimicrob. Agents Chemother.53(11) , 4712–4717 (2009).
   PubMed Web of Science ®Google Scholar
• Farrell DJ , MoetGJ, RhombergPR, SaderHS, JonesRN: Activity of ceftaroline against recent (2009) and multidrug-resistant Streptococcus pneumoniae isolates from Europe and the United States.Clin. Microbiol. Infect.16(S2) , S557 (2010).
   Google Scholar
• Jacobs MR , GoodCE, WindauARet al. : Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.Antimicrob. Agents Chemother.54(6) , 2716–2719 (2010).
   PubMed Web of Science ®Google Scholar
• Jacqueline C , CaillonJ, LeMabecque Vet al.: In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin.Antimicrob. Agents Chemother.53(12) , 5300–5302 (2009).
   PubMed Web of Science ®Google Scholar
• Mushtaq S , WarnerM, GeY, KanigaK, LivermoreDM: In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.J. Antimicrob. Chemother.60(2) , 300–311 (2007).
   PubMed Web of Science ®Google Scholar
• Vidaillac C , LeonardSN, SaderHS, JonesRN, RybakMJ: In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.Antimicrob. Agents Chemother.53(6) , 2360–2366 (2009).
   PubMed Web of Science ®Google Scholar
• Mushtaq S , WarnerM, WilliamsG, CritchleyI, LivermoreDM: Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae.J. Antimicrob. Chemother.65(7) , 1428–1432 (2010).
   PubMed Web of Science ®Google Scholar
• Citron DM , TyrrellKL, MerriamCV, GoldsteinEJ: In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.Antimicrob. Agents Chemother.54(4) , 1627–1632 (2010).
   PubMed Web of Science ®Google Scholar
• Mushtaq S , LivermoreDM: AmpC induction by ceftaroline.J. Antimicrob. Chemother.65(3) , 586–588 (2010).
   PubMed Web of Science ®Google Scholar
• Andes D , CraigWA: Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic–pharmacodynamic target.Antimicrob. Agents Chemother.50(4) , 1376–1383 (2006).
   PubMed Web of Science ®Google Scholar
• Pankuch GA , AppelbaumPC: Postantibiotic effect of ceftaroline against Gram-positive organisms.Antimicrob. Agents Chemother.53(10) , 4537–4539 (2009).
   PubMed Web of Science ®Google Scholar
• Ge Y , HubbelA: In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M). Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September 2006.
   Google Scholar
• Ge Y , RedmanR, FlorenL, LiaoS, WiklerM: Single-dose phamacokinetics of ceftaroline (PPI-0903) in healthy subjects. Presented at:46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September2006.
   Google Scholar
• Ge Y , RedmanR, FlorenL, LiaoS, WiklerM: The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. Presented at:46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September2006.
   Google Scholar
• Jacqueline C , CaillonJ, MiegevilleAF: Penetration of ceftaroline (PPI-0903), a new cephalosporin, into lung tissues: measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit. Presented at:46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September2006.
   Google Scholar
• Iizawa Y , NagaiJ, IshikawaTet al. : In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.J. Infect. Chemother.10(3) , 146–156 (2004).
   PubMedGoogle Scholar
• Jacqueline C , CaillonJ, LeMabecque Vet al. : In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.Antimicrob. Agents Chemother.51(9) , 3397–3400 (2007).
   PubMed Web of Science ®Google Scholar
• Jacqueline C , AmadorG, CaillonJet al. : Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis.J. Antimicrob. Chemother.65(8) , 1749–1752 (2010).
   PubMed Web of Science ®Google Scholar
• Xiong YQ , LiY, AbdelsayedGA, BiekD, BayerAS: Real-time evaluation of ceftaroline, a new cephalosporin, versus vancomycin and daptomycin in a rat S. aureus endocarditis model using in vivo bioluminescent imaging. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 17–20 September2007.
   Google Scholar
• Panagiotidis G , BackstromT, Asker-HagelbergC, JandourekA, WeintraubA, NordCE: Effect of ceftaroline on normal human intestinal microflora.Antimicrob. Agents Chemother.54(5) , 1811–1814 (2010).
   PubMed Web of Science ®Google Scholar